Akebia Therapeutics Total Assets 2011-2026 | AKBA

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Akebia Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
377 M	221 M	242 M	356 M	529 M	644 M	771 M	997 M	364 M	300 M	143 M	111 M	34.7 M	2.24 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
997 M	2.24 M	364 M

Quarterly Total Assets Akebia Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
364 M	346 M	310 M	221 M	207 M	220 M	-	242 M	235 M	254 M	277 M	356 M	436 M	530 M	535 M	526 M	602 M	612 M	629 M	644 M	644 M	644 M	644 M	771 M	771 M	771 M	771 M	997 M	997 M	997 M	997 M	364 M	364 M	364 M	364 M	300 M	300 M	300 M	300 M	143 M	143 M	143 M	143 M	111 M	111 M	111 M	111 M	34.7 M	34.7 M	34.7 M	34.7 M	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
997 M	34.7 M	407 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
Alector ALEC	293 M	$ 2.13	-12.55 %	$ 219 M	USA
Acer Therapeutics ACER	11.6 M	-	2.71 %	$ 14 M	USA
BioCardia BCDA	2.99 M	$ 1.37	6.2 %	$ 29 M	USA
Black Diamond Therapeutics BDTX	123 M	$ 2.4	-2.83 %	$ 132 M	USA
BioLineRx Ltd. BLRX	38.9 M	$ 2.8	-1.06 %	$ 908 M	Israel
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
BioXcel Therapeutics BTAI	38.3 M	$ 1.64	-1.8 %	$ 4.16 M	USA
AgeX Therapeutics AGE	12 M	-	-10.17 %	$ 12.2 K	USA
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
BeyondSpring BYSI	34.3 M	$ 1.44	6.3 %	$ 58.1 M	USA
Cabaletta Bio CABA	254 M	$ 3.34	0.6 %	$ 3.9 M	USA
AbCellera Biologics ABCL	1.36 B	$ 3.7	2.49 %	$ 1.11 B	Canada
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	14.8 M	-	-18.52 %	$ 27.3 M	Britain
Codexis CDXS	149 M	$ 1.05	3.47 %	$ 77.1 M	USA
Cerus Corporation CERS	201 M	$ 2.6	1.56 %	$ 480 M	USA
Certara CERT	1.56 B	$ 7.17	1.27 %	$ 1.15 B	USA
Cullinan Management CGEM	622 M	$ 15.91	2.65 %	$ 931 M	USA
Compugen Ltd. CGEN	115 M	$ 2.28	25.97 %	$ 204 M	Israel
ARCA biopharma ABIO	396 M	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Acasti Pharma ACST	72 M	-	4.01 %	$ 150 M	Canada
Coherus BioSciences CHRS	630 M	$ 1.66	-0.9 %	$ 156 M	USA
Adverum Biotechnologies ADVM	180 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
AIkido Pharma AIKI	47.1 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
Cellectis S.A. CLLS	384 M	$ 3.88	-	$ 116 M	France
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	62.2 M	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	119 M	-	4.14 %	$ 49.1 M	USA
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA
Aeterna Zentaris AEZS	35.1 M	-	5.93 %	$ 314 M	Canada
Ampio Pharmaceuticals AMPE	5.74 M	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
CNS Pharmaceuticals CNSP	8.7 M	$ 3.1	-0.44 %	$ 1.18 M	USA
Aravive ARAV	62.2 M	-	-13.39 %	$ 1.45 M	USA
Cocrystal Pharma COCP	13.5 M	$ 1.02	-0.97 %	$ 10.4 M	USA
Aptose Biosciences APTO	10.1 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
Collegium Pharmaceutical COLL	1.66 B	$ 42.0	0.79 %	$ 1.33 B	USA
Corcept Therapeutics Incorporated CORT	837 M	$ 35.61	-0.25 %	$ 3.7 B	USA
Athira Pharma ATHA	58.8 M	-	-	$ 269 M	USA
Aridis Pharmaceuticals ARDS	14.7 M	-	17.91 %	$ 11.1 M	USA